D16-M1P2

D16-M1P2 is a first-in-class proteolysis-targeting chimera (PROTAC) developed by Insilico Medicine using their AI-driven Chemistry42 platform. It is designed to target Membrane-associated Tyrosine/Threonine Protein Kinase 1 (PKMYT1), a key regulator of the cell cycle. D16-M1P2 features a unique dual mechanism of action, simultaneously inducing the degradation of PKMYT1 through the ubiquitin-proteasome system and directly inhibiting its kinase activity. Preclinical studies have demonstrated that the compound is highly selective, shows potent anti-tumor activity in xenograft models, and possesses favorable oral bioavailability. D16-M1P2 is currently in the pre-candidate validation stage for the treatment of cancer, offering a more durable effect compared to traditional PKMYT1 inhibitors.